Business
P.M. Edition for Feb. 24. Johnson & Johnson's one-dose Covid-19 vaccine could get Food and Drug Administration approval as early as this weekend. But the shot has been shown to be less effective than the vaccines from Moderna and Pfizer. Medicine and FDA reporter Tom Burton joins host Annmarie Fertoli to explain why it is still a boon to vaccination efforts. Learn more about your ad choices. Visit megaphone.fm/adchoices